MedTrace Logo

BSCU1 and Immune Function

NCT05403398 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-01-08

No results posted yet for this study

Summary

The current study aims to explore a range of possible pathways by which BSCU1 could beneficially modulate the immune system, in three target populations representing the general population.

Conditions

  • General Population

Interventions

DIETARY_SUPPLEMENT

B. subtilis CU1

2 billion CFUs daily, for 4 weeks

Sponsors & Collaborators

  • NIZO Food Research

    collaborator OTHER

  • Lesaffre International

    lead INDUSTRY

Principal Investigators

  • Jean-François Jeanne · Lesaffre Group

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-07
Primary Completion
2022-10-18
Completion
2023-03-20

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05403398 on ClinicalTrials.gov